Solid Tumor
Conditions
Brief summary
This is an open-label, multi-center phase 1 study. The trial, consisting of Part 1a dose confirmation and Part 1b dose expansion, is designed to evaluate the safety, tolerability, PK/PD and preliminary efficacy of HBM4003 in combination with pembrolizumab in patients with advanced NSCLC and other solid tumors.
Detailed description
subjects will be treated with HBM4003 in combination with pembrolizumab for up to 2 years or until confirmed disease progression, unacceptable tolerability or treatment discontinuation through withdrawal of consent occurs, whichever happens first. This trial consists of : * A screening period: 28 days * A treatment period: * Part 1a dose confirmation study * Part 1b dose expansion study * A post-treatment follow-up period, including * A safety follow-up period: 28 days after the last dose of study drug; * Post-treatment follow-up visit: day 84 after the last dose of study drug; * Survival follow-up.
Interventions
DRUGHBM4003 and pembrolizumab
Subjects will be treated with HBM4003 and pembrolizumab on Day 1 during each 21-day cycles.
Sponsors
Harbour BioMed (Guangzhou) Co. Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Male or female patients ≥18 years old at the time of signing the informed consent and ≤ 75 years old at the time of enrollment. * Patients for Part 1a: patients diagnosed with advanced or recurrent solid tumors. * Patients for Part 1b: patients diagnosed with metastatic NSCLC and confirmed with negative tumor PD-L1 expression (TPS\<1%). * Patients for Part 1b dose expansion study: have never received systemic therapies as primary therapy for advanced or metastatic diseases. * Patients must be able to provide fresh tumor tissues or archived tumor tissues. * Patients whose estimated survival time is more than 3 months. * Patients with at least one measurable lesion at baseline according to RECIST (version 1.1). * Patients with Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 1. * Patients whose organ function must meet the study requirements. * Males or females with childbearing potential need to use an effective contraceptive method. * Willing and able to comply with study-specified visits schedule, treatment plan, laboratory examination and other study procedures.
Exclusion criteria
* NSCLC patients with EGFR-sensitive mutations or an ALK translocation based on diagnosis results. * Patients who are simultaneously participating in another clinical study, unless the study is an observational (non-interventional) clinical study or the patient is already in the survival follow-up period of the interventional study. * Patients with a medical history of severe allergic diseases, a history of severe drug allergies, and are known or suspected allergy to macromolecular protein preparations or HBM4003 or pembrolizumab excipients. * Previous and concomitant drugs or treatments to be excluded like CTLA4, PD-1,PD-L1. * Insufficient completely recovery from previous treatments. * Diseases that may affect the efficacy and safety of the investigational product. * A history of other malignant diseases within 5 years before the first dose. * Active brain metastasis or leptomeningeal metastasis during screening or previous with imaging evidence (based on CT or MRI assessment). * Patients who have received palliative radiotherapy for non-central nervous system lesions within 2 weeks before the first dose. * Patients who have received more than 30 Gy of lung radiation therapy within 6 months before the first dose. * A history of interstitial lung disease or non-infectious pneumonia. * Patients with pleural effusion, pericardial effusion, or ascites. * Patients that may have other conditions that affect the efficacy or safety evaluation of this study (such as mental disorder, alcoholism, drug abuse, etc.) . * Women who are pregnant or breastfeeding, or who plan to become pregnant during the study period and within 3 months after the last dose of study drug.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part 1a: Number of subjects with DLT in each dose group within 1 cycles (21 days) after the first drug administration | approximate 21 days | DLT observation period was defined as one treatment cycles with a total of 21 days |
| Part 1b: ORR | maximum 2 years | Proportion of subjects with complete response (CR) and partial response (PR) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Part 1a: Duration of Response, DOR | maximum 2 years | Calculate the duration from the first confirmed CR or PR to the date of disease progression or death (for any reason) |
| Part 1a: Duration of Disease Control, DDC | maximum 2 years | For subjects with Cr, PR or SD, the duration from the time of initial administration to the date of disease progression or death (for any reason) was calculated |
| Cmax | maximum 2 years | Peak Plasma Concentration |
| Tmax | maximum 2 years | Time to reach maximum serum concentration |
| AUC0-last | maximum 2 years | Area under the plasma concentration versus time curve from time zero to last |
| AUC0-tau | maximum 2 years | Area under the serum concentration versus time curve from time zero to the dosing interval tau |
| UC0-inf | maximum 2 years | Area under the serum concentration versus time curve from time zero to infinity |
| Vss | maximum 2 years | Volume of distribution at steady state |
| CL | maximum 2 years | Clearance |
| Part 1a: Disease Control Rate, DCR | maximum 2 years | including proportion of subjects with complete response (CR) and partial response (PR) and stable disease (SD) |
| Part 1a: Immunogenicity of HBM4003 and pembrolizumab | maximum 2 years | including the occurrence of positive anti-drug antibodies (ADA). The occurrence of neutralizing antibodies for subjects with positive ADA |
| Part 1b: Number of subjects experiencing at least one treatment-related AE | maximum 2 years | Evaluate safety |
| Part 1b: DCR | maximum 2 years | including proportion of subjects with CR, PR and SD |
| Part 1b: DOR | maximum 2 years | calculate the duration from the first confirmed CR or PR to the date of disease progression or (for any reason) death. |
| Part 1b: DDC | maximum 2 years | for subjects with CR, PR or SD, calculate the duration from the time of initial medication to the day of disease progression or (for any reason) death |
| Part 1b: Overall survival (OS) | maximum 2 years | the length of time from the start of treatment to the death of the subject (for any reason) |
| Part 1b: Progression-free survival (PFS) | maximum 2 years | the length of time from the beginning of treatment to the beginning of disease progression or death (for any reason) |
| Part 1b: Immunogenicity of HBM4003 and pembrolizumab | maximum 2 years | including the occurrence of positive anti-drug antibodies (ADA). The occurrence of neutralizing antibodies for subjects with positive ADA. |
| t1/2 | maximum 2 years | Terminal half-life |
| Part 1a: ORR | maximum 2 years | including proportions of subjects with complete response (CR) and partial response (PR) |
Contacts
Primary ContactXi LIU
Backup ContactPeter ZHAO
Outcome results
None listed